Press release
Small Cell Lung Cancer Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers
Explore our latest breakthroughs in Small Cell Lung Cancer Research. Learn more about our innovative pipeline today! @ Small Cell Lung Cancer Pipeline Outlook [https://www.delveinsight.com/sample-request/small-cell-lung-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Small Cell Lung Cancer Pipeline Report
* In October 2024:- Hoffmann-La Roche- A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer. The purpose of this multicenter study in China is to evaluate the safety and efficacy of tiragolumab plus atezolizumab and carboplatin and etoposide (CE) compared with placebo plus atezolizumab and CE in participants with untreated extensive-stage small cell lung cancer.
* In October 2024:- Merck Sharp & Dohme LLC- A Phase 1b/2 Study to Evaluate the Efficacy and Safety of Investigational Agents as Monotherapy or in Combination With Pembrolizumab for the Treatment of Participants With PD-1/L1-refractory Extensive-Stage Small Cell Lung Cancer in Need of Second-Line Therapy (KEYNOTE-B98). This study is a rolling arm study of investigational agents as monotherapy or in combination with pembrolizumab in participants with anti-programmed cell death 1 (PD-1)/ programmed cell death ligand 1 (PD-L1) refractory ES-SCLC in need of second-line treatment. This study will have 2 parts: an initial safety lead-in to determine safety and tolerability for experimental combinations of investigational agents without an established recommended phase 2 dose (RP2D) followed by an efficacy evaluation.
* In October 2024:- Mirati Therapeutics Inc.- A Randomized Study of Two Dosing Regimens of Adagrasib in Patients With Previously Treated Non-Small Cell Lung Cancer With KRAS G12C Mutation. CA239-0012 is a phase 2 study of adagrasib monotherapy in which patients are randomized between two dosing regimens. The study will evaluate the efficacy of two dosing regimens of adagrasib (600 mg BID without regard to food versus 400 mg BID with food) in patients with NSCLC with KRAS G12C mutation and who have received prior treatment with a platinum-based regimen and immune checkpoint inhibitor therapy.
* In October 2024- Novartis Pharmaceuticals- The Drugs Controller General of India (DCGI) has granted approval for Rahika Registered (Capmatinib) film-coated tablet 150 and 200 mg for the treatment of adult patients with advanced/metastatic NSCLC whose tumors have a mutation that leads to MET exon 14 skipping mutation with condition to perform a Phase IV clinical trial in Indian patients. As recommended by DCGI, this Phase IV study has been planned to evaluate the safety and efficacy of capmatinib in treatment of adult Indian patients with advanced/metastatic NSCLC whose tumors have a MET exon 14 skipping mutation positive advanced NSCLC in any line of therapy.
* In October 2024:- Boehringer Ingelheim- This study is open to adults with small cell lung cancer and other neuroendocrine tumours. The study is in people with advanced cancer for whom previous treatment was not successful or no standard treatment exists. The purpose of this study is to find a suitable dose of BI 764532 that people with advanced cancer can tolerate when taken alone. 2 different doses of BI 764532 are tested in this study. Another purpose is to check whether BI 764532 can make tumours shrink. BI 764532 is an antibody-like molecule (DLL3/CD3 bispecific) that may help the immune system fight cancer.
* In October 2024:- AstraZeneca- This is a phase III, randomized, open-label, multicenter, global study to determine the efficacy and safety of combining durvalumab plus-minus tremelimumab with platinum based chemotherapy (EP) followed by durvalumab plus-minus tremelimumab maintenance therapy versus EP alone as first-line treatment in patients with extensive-stage small-cell lung cancer.
* DelveInsight's Small Cell Lung Cancer pipeline report depicts a robust space with 100+ active players working to develop 100+ pipeline therapies for Small Cell Lung Cancer treatment.
* The leading Small Cell Lung Cancer Companies include Staidson (Beijing) Biopharmaceuticals Co., Ltd, Cartesian Therapeutics, GEn1E Lifesciences, Aqualung Therapeutics Corp., Theratome Bio, Meridigen Biotech Co., Ltd., Dompe Farmaceutici S.p.A., Veru Healthcare, Windtree Therapeutics, MiNK Therapeutics, Avalo Therapeutics, Inc., Cynata Therapeutics Limited, Thiogenesis Therapeutics, Inc., Arch Biopartners, Ibudilast , and others.
* Promising Small Cell Lung Cancer Therapies in the various stages of development include Amivantamab, Lazertinib, Pemetrexed 500 mg, AL8326 tablets, durvalumab , and others.
Stay informed about the cutting-edge advancements in Small Cell Lung Cancer treatments. Download for updates and be a part of the revolution in care @ Small Cell Lung Cancer Clinical Trials Assessment [https://www.delveinsight.com/sample-request/small-cell-lung-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Small Cell Lung Cancer Emerging Drugs Profile
* AMG 757: Amgen
AMG 757 is a half-life extended (HLE) anti- delta-like ligand 3 (DLL3) x anti-CD3 BiTE (bispecific T cell engager) molecule. It is being investigated in Phase I clinical studies for the treatment of prostate cancer and Small cell lung cancer.
* APG-1252: Ascentage Pharma
APG-1252 is a highly potent, small-molecule based Bcl-2 family protein inhibitor drug. APG-1252 is designed to treat SCLC, NSCLC, lymphoma, and other solid tumors by selectively blocking Bcl-2 and Bcl-xL to restore the apoptosis process. The drug is in Phase I/II clinical studies for the treatment of SCLC.
Learn more about Small Cell Lung Cancer Drugs opportunities in our groundbreaking Psoriasis Research and development projects @ Small Cell Lung Cancer Unmet Needs [https://www.delveinsight.com/sample-request/small-cell-lung-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Small Cell Lung Cancer Companies
Staidson (Beijing) Biopharmaceuticals Co., Ltd, Cartesian Therapeutics, GEn1E Lifesciences, Aqualung Therapeutics Corp., Theratome Bio, Meridigen Biotech Co., Ltd., Dompe Farmaceutici S.p.A., Veru Healthcare, Windtree Therapeutics, MiNK Therapeutics, Avalo Therapeutics, Inc., Cynata Therapeutics Limited, Thiogenesis Therapeutics, Inc., Arch Biopartners, Ibudilast, and others.
Small Cell Lung Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Oral
* Parenteral
* Intravitreal
* Subretinal
* Topical
* Molecule Type
Small Cell Lung Cancer Products have been categorized under various Molecule types such as
* Monoclonal Antibody
* Peptides
* Polymer
* Small molecule
* Gene therapy
* Product Type
Discover the latest advancements in Small Cell Lung Cancer treatment by visiting our website. Stay informed about how we're transforming the future of disease @ Small Cell Lung Cancer Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/small-cell-lung-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Small Cell Lung Cancer Pipeline Report
* Coverage- Global
* Small Cell Lung Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Small Cell Lung Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
* Small Cell Lung Cancer Companies- Staidson (Beijing) Biopharmaceuticals Co., Ltd, Cartesian Therapeutics, GEn1E Lifesciences, Aqualung Therapeutics Corp., Theratome Bio, Meridigen Biotech Co., Ltd., Dompe Farmaceutici S.p.A., Veru Healthcare, Windtree Therapeutics, MiNK Therapeutics, Avalo Therapeutics, Inc., Cynata Therapeutics Limited, Thiogenesis Therapeutics, Inc., Arch Biopartners, Ibudilast, and others.
* Small Cell Lung Cancer Therapies- Amivantamab, Lazertinib, Pemetrexed 500 mg, AL8326 tablets, durvalumab, and others.
For a detailed overview of our latest research findings and future plans, read the full details of Small Cell Lung Cancer Pipeline on our website @ Small Cell Lung Cancer Emerging Drugs and Companies [https://www.delveinsight.com/sample-request/small-cell-lung-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* Small Cell Lung Cancer: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Small Cell Lung Cancer - DelveInsight's Analytical Perspective
* In-depth Commercial Assessment
* Small Cell Lung Cancer Collaboration Deals
* Late Stage Products (Phase III)
* Pembrolizumab: Merck & Co
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Dostarlimab: GlaxoSmithKline
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* AMG 757: Amgen
* Drug profiles in the detailed report.....
* Preclinical/Discovery Stage Products
* S 055746: Vernalis
* Drug profiles in the detailed report.....
* Inactive Products
* Small Cell Lung Cancer Key Companies
* Small Cell Lung Cancer Key Products
* Small Cell Lung Cancer- Unmet Needs
* Small Cell Lung Cancer- Market Drivers and Barriers
* Small Cell Lung Cancer- Future Perspectives and Conclusion
* Small Cell Lung Cancer Analyst Views
* Small Cell Lung Cancer Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=small-cell-lung-cancer-pipeline-therapeutics-assessment-companies-products-unmet-needs-market-drivers-and-barriers]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Small Cell Lung Cancer Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers here
News-ID: 3715916 • Views: …
More Releases from ABNewswire
Uplers Highlights 2025 Trend: Brands Compete to Hire Graphic Designers With Adva …
The design industry is entering a new era in 2025 and the years to come. Creativity and artificial intelligence are merging to reshape how visual content is being produced. For brands, this no longer is a trend to monitor, instead it's a race to secure the right and skilled talent. Companies are fiercely competing to hire graphic designers who can harness AI tools to deliver innovation, speed, and consistency across…
Inside Uplers Latest Report: What Companies Should Know About Angular Developer …
Angular continues to be one of the widely adopted front-end frameworks for dynamic and scalable app development. With digital products becoming increasingly complex, global hiring managers are continuing to face the challenge of finding Angular talent for balancing cost and availability.
In response to this, Uplers is publishing new salary insights based on the evolving hiring trends for supporting companies in shaping their competitive strategies to hire Angular developers [https://www.uplers.com/hire-angularjs-developers/]. The…
The Moss Way: Unlocking the True Power of Irish Sea Moss for Modern Wellness
London, United Kingdom - 7 Oct, 2025 - As the wellness industry evolves, a growing number of people are turning back to nature's timeless remedies - and few are as powerful or as misunderstood as Irish Sea Moss. Leading this natural health renaissance is The Moss Way, a UK-based wellness brand redefining what it means to nourish the body with pure, sustainably sourced superfoods. With a focus on authenticity, science,…
New Outdoor Retailer Feeling My Adventure Empowers Digital Detox Through Compreh …
The outdoor retail sector welcomes Feeling My Adventure, a new e-commerce venture operated by Ingrid K Santana Ramirez LLC, offering comprehensive equipment solutions for camping, survival preparedness, and outdoor recreation activities. Launching at feelingmyadventure.com, the platform distinguishes itself through a philosophy emphasizing nature's role in personal restoration and the importance of disconnecting from digital saturation to rediscover authentic human experiences.
Market timing for the launch aligns with growing societal recognition of…
More Releases for Small
Succeeding Small Launches Small Business Give-Back Giveaway in Celebration of Sm …
Succeeding Small Launches Small Business Give-Back Giveaway in Celebration of Small Business Month
Honoring Local Colorado Springs Businesses That Make a Difference in Their Community
COLORADO SPRINGS, CO - Succeeding Small, a go-to guide for small business success in small business marketing, is celebrating Small Business Month with the launch of its Small Business Give-Back Giveaway - a contest aimed at honoring the small, service-based businesses that make a meaningful difference in…
Small Molecules, Big Impact: The Rise of the Small Molecule Immunomodulators Mar …
Small Molecule Immunomodulators Market worth $270.8 Bn by 2031 - Exclusive Report by InsightAce Analytic Pvt. Ltd.
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Small Molecule Immunomodulators Market - (By Product (Disposable, Reusable), By Application (Colorectal, Thoracic, Orthopedic, Ophthalmology, Neurosurgery, Cardiac Surgery, Gynecology, Others), By End User (Hospitals, Ambulatory Surgical Centers, Clinics, Others)), Trends, Industry Competition Analysis, Revenue and Forecast To 2031."
According to…
Powering Small: Small Gas Engines Market Advances (2023-2032)
"According to the research report, the global small gas engines market was valued at USD 2.75 billion in 2022 and is expected to reach USD 4.23 billion by 2032, to grow at a CAGR of 4.4% during the forecast period."
Polaris Market Research has recently published the latest update on Small Gas Engines Market: By Size, Latest Trends, Share, Huge Growth, Segments, Analysis and Forecast, 2030 that offers detailed market analysis,…
Small Batch Freeze Dryer Market: Increasing Demand for Small-scale Freeze Drying …
Global Small Batch Freeze Dryer Market Overview:
The Small Batch Freeze Dryer market is a broad category that includes a wide range of products and services related to various industries. This market comprises companies that operate in areas such as consumer goods, technology, healthcare, and finance, among others.
In recent years, the Small Batch Freeze Dryer market has experienced significant growth, driven by factors such as increasing consumer demand, technological advancements, and…
Global Small Gas Engines Market, Global Small Gas Engines Industry, Covid-19 Imp …
The Small Gas Engines market is expected to grow from USD X.X million in 2020 to USD X.X million by 2026, at a CAGR of X.X% during the forecast period. The Global Small Gas Engines Market report is a comprehensive research that focuses on the overall consumption structure, development trends, sales models and sales of top countries in the global Small Gas Engines market. The report focuses on well-known providers…
Small Appliances Market: Strategic Assessment of Emerging Technologies in Small …
Small appliances market is forecasted to grow substantially in all market segments through 2016 owing to the rise in living standards and need for more comfort. Small appliance industry consists of home appliances that are movable or partially movable and can be used on tables, counters, or other platforms. The growth of small appliances market is expected to be driven by product innovation, upgradation of existing products, and value-added features…
